Journal
DRUGS
Volume 76, Issue 8, Pages 901-905Publisher
ADIS INT LTD
DOI: 10.1007/s40265-016-0579-y
Keywords
-
Categories
Ask authors/readers for more resources
Ixekizumab (Taltz (R)) is a humanised monoclonal immunoglobulin G antibody developed by Eli Lilly and Company that has been approved in the USA as a treatment for plaque psoriasis. Ixekizumab is a specific inhibitor of interleukin-17A (IL-17A), a pro-inflammatory cytokine that has a role in the development of several inflammatory conditions. This article summarizes the milestones in the development of ixekizumab leading to this first approval for plaque psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available